Form D · Biotechnology
QUANTRX BIOMEDICAL CORP
Doylestown, PA · CIK 0000820608
Offering snapshot reported Aug 14, 2009 · SEC filing
- Reported sold
- $406M Offering amount: $406M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 30, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2009 | Initial | $406,039,700 | No comparison | 13 | SEC filing |
| Sep 18, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 18, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 18, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 22, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-82060-8S
Source: Form D, filed Aug 14, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sasha Afanassiev | Executive |
| William H. Fleming | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 South Main Street Suite 300
Doylestown, PA, 18901
Doylestown, PA, 18901